← Leaderboards
Andrew Edward Moran
Columbia University Health Sciences
$8,253,524
Attributed
$12,031,180
Total exposure
5
Grants
5
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.3M · FY2008–22$2.5M$1.9M$1.3M$625K$0
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
Funding mix
By agency
NIH$12,031,180 · 5
By mechanism
R01$11,381,425 · 4
K08$649,755 · 1
Top collaborators
- Adam P Bress4 shared
- Sarah D De Ferranti4 shared
- William S Weintraub4 shared
Most similar at Columbia University Health Sciences
Same institution · by research overlap
- Robert Garofalo$27,675,266
- Daichi Shimbo$28,917,433
- Richard J Deckelbaum$9,877,597
- J. Lawrence Aber$4,449,284
- Brandon K Bellows$708,750
Others in their field
Top investigators on “Base”
- Sonia M Thomas · Research Triangle Institute$700,865,642
- David Heimbrook · Leidos Biomedical Research, Inc.$613,567,095
- David Divins · Consortium For Ocean Leadership, Inc$609,772,544
- Larry Arthur$521,411,998
- Leonard Freedman · Leidos Biomedical Research, Inc.$515,995,429
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$507,042,060
Research focus
BaseCardiovascular Disorder RiskGuidelinesHealth EconomicsEventCost EffectiveHigh RiskComputer SimulationCost EffectivenessHypertensionCostPreventAdultFuturePrevalenceHealthcareCardiovascular DiseasesHealth BenefitClinical PracticeEpidemiologyBiometryClinical TrialsEconomic EvaluationPharmaceutical Preparations
Grant awards (23)
Familial hypercholesterolemia screening in children: population impact of phenotype, genotype, and cascade approaches$766,330
R01 · FY2022 · HL · contact PI
Familial hypercholesterolemia screening in children: population impact of phenotype, genotype, and cascade approaches$788,885
R01 · FY2021 · HL · contact PI
Patient Level Prediction of Clinical Outcomes and Cost-Effectiveness in SPRINT (Optimize-SPRINT)$762,748
R01 · FY2021 · HL · contact PI
Familial hypercholesterolemia screening in children: population impact of phenotype, genotype, and cascade approaches$804,498
R01 · FY2020 · HL · contact PI
Patient Level Prediction of Clinical Outcomes and Cost-Effectiveness in SPRINT (Optimize-SPRINT)$775,853
R01 · FY2020 · HL · contact PI
Familial hypercholesterolemia screening in children: population impact of phenotype, genotype, and cascade approaches$894,544
R01 · FY2019 · HL · contact PI
Patient Level Prediction of Clinical Outcomes and Cost-Effectiveness in SPRINT (Optimize-SPRINT)$794,534
R01 · FY2019 · HL · contact PI
Model Based Approach to Improving Hypertension Control in Populations$623,643
R01 · FY2019 · HL · contact PI
Patient Level Prediction of Clinical Outcomes and Cost-Effectiveness in SPRINT (Optimize-SPRINT)$892,656
R01 · FY2018 · HL · contact PI
Model Based Approach to Improving Hypertension Control in Populations$557,521
R01 · FY2018 · HL · contact PI
Potential future benefits of cardiovascular risk factor control in todayâs young adults$398,871
R01 · FY2018 · HL · contact PI
Model Based Approach to Improving Hypertension Control in Populations$574,266
R01 · FY2017 · HL · contact PI
Potential future benefits of cardiovascular risk factor control in todayâs young adults$398,875
R01 · FY2017 · HL · contact PI
Model Based Approach to Improving Hypertension Control in Populations$634,613
R01 · FY2016 · HL · contact PI
Potential future benefits of cardiovascular risk factor control in todayâs young adults$413,831
R01 · FY2016 · HL · contact PI
Effectiveness of treat-to-target versus risk-based blood pressure guidelines$410,697
R01 · FY2013 · HL · contact PI
Effectiveness of treat-to-target versus risk-based blood pressure guidelines$432,679
R01 · FY2012 · HL · contact PI
Forecasting the Cardiovascular Disease Epidemic in China$129,951
K08 · FY2012 · HL · contact PI
Comparative effectiveness analysis of treat-to-target and risk-based blood pressu$456,381
R01 · FY2011 · HL · contact PI
Forecasting the Cardiovascular Disease Epidemic in China$129,951
K08 · FY2011 · HL · contact PI
Forecasting the Cardiovascular Disease Epidemic in China$129,951
K08 · FY2010 · HL · contact PI
Forecasting the Cardiovascular Disease Epidemic in China$129,951
K08 · FY2009 · HL · contact PI
Forecasting the Cardiovascular Disease Epidemic in China$129,951
K08 · FY2008 · HL · contact PI